Free tool
FAERS Monitor: Pifeltro
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210806 or its brand name (Pifeltro, Doravirine). Reports on generic versions are filed under their own applications.
Reports
788
Serious
620
79% of reports
Hospitalization
198
Death reported
75
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- anxiety71
- pain71
- emotional distress65
- anhedonia53
- death53
- chronic kidney disease48
- drug resistance43
- pathogen resistance42
- nausea41
- drug ineffective38
- treatment noncompliance37
- off label use34
- virologic failure34
- renal failure33
- product dose omission issue32
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2016 | 5 |
| 2018 | 6 |
| 2019 | 49 |
| 2020 | 79 |
| 2021 | 113 |
| 2022 | 121 |
| 2023 | 146 |
| 2024 | 112 |
| 2025 | 90 |
| 2026 | 65 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,371 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| virologic failureSignal | 34 | 169.8 | 122.1 | 5,505 |
| pathogen resistanceSignal | 42 | 123.6 | 92.0 | 4,963 |
| anhedoniaSignal | 53 | 53.9 | 41.6 | 2,699 |
| drug resistanceSignal | 43 | 44.8 | 33.5 | 1,795 |
| treatment noncomplianceSignal | 37 | 18.1 | 13.2 | 581 |
| chronic kidney diseaseSignal | 48 | 16.9 | 12.8 | 703 |
| emotional distressSignal | 65 | 14.3 | 11.4 | 797 |
| anxietySignal | 71 | 6.7 | 5.3 | 340 |
| renal failureSignal | 33 | 6.6 | 4.8 | 153 |
| painSignal | 71 | 3.1 | 2.5 | 101 |
| product dose omission issueSignal | 32 | 2.9 | 2.1 | 39 |
| death | 53 | 1.6 | 1.3 | 13 |
| nausea | 41 | 1.4 | 1.0 | 4 |
| off label use | 34 | 1.0 | 0.7 | 0 |
| drug ineffective | 38 | 0.8 | 0.6 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.